 CHERRY HILL, NJ and TORONTO, CANADA, Aug. 19, 2021 GLOBE NEWSWIRE -- Vyant Bio, Inc., Nasdaq: VYNT, a leading biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and Cyclica, Inc., the partner of choice for data driven drug discovery, today announced a non-exclusive strategic collaboration combining Vyant Bios patient-derived complex organoid biology alongside Cyclicas proteome-wide, Artificial Intelligence AI enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder CDD, a severe neurodevelopmental epilepsy disorder with no effective treatments or cure. 